Identification

Name
Meclofenamic acid
Accession Number
DB00939  (APRD01090)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]

Structure
Thumb
Synonyms
  • Acide meclofenamique
  • Acido meclofenamico
  • Acidum meclofenamicum
  • Meclofenamate
  • N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
  • N-(2,6-Dichloro-m-tolyl)anthranilic acid
  • N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
External IDs
CI 583 / CI-583 / Cl 583 / INF 4668 / INF-4668
Product Ingredients
IngredientUNIICASInChI Key
Meclofenamate sodium94NJ818U2W67254-91-5QHJLLDJTVQAFAN-UHFFFAOYSA-M
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meclofenamate SodiumCapsule50 mg/1OralMylan Pharmaceuticals1986-09-03Not applicableUs
Meclofenamate SodiumCapsule100 mg/1OralMylan Pharmaceuticals1986-09-03Not applicableUs
International/Other Brands
Ethos (Yung Shin) / Eucome (U-Liang) / Meclomen (Pfizer)
Categories
UNII
48I5LU4ZWD
CAS number
644-62-2
Weight
Average: 296.149
Monoisotopic: 295.016684015
Chemical Formula
C14H11Cl2NO2
InChI Key
SBDNJUWAMKYJOX-UHFFFAOYSA-N
InChI
InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
IUPAC Name
2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1

Pharmacology

Indication

For the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.

Associated Conditions
Pharmacodynamics

Meclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.

Mechanism of action

The mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
AArachidonate 5-lipoxygenase
inhibitor
Human
UPotassium voltage-gated channel subfamily KQT member 2
other
Human
UPotassium voltage-gated channel subfamily KQT member 3
other
Human
Absorption

Rapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.

Volume of distribution
  • 9.1 to 43.2 L
Protein binding

Greater than 99% bound to plasma proteins over a wide drug concentration range.

Metabolism

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

Route of elimination

Other metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.

Half life

In a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.

Clearance
  • Oral cl=206 mL/min
Toxicity

After a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Meclofenamic acid.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMeclofenamic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolMeclofenamic acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetaminophen.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Meclofenamic acid.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Meclofenamic acid.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.Approved
AliskirenMeclofenamic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Meclofenamic acid.Experimental
AlprenololMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide.Approved
AmikacinMeclofenamic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideMeclofenamic acid may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aminosalicylic Acid.Approved
AmiodaroneMeclofenamic acid may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodMeclofenamic acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Meclofenamic acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Meclofenamic acid.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.Approved, Investigational
Antithrombin III humanMeclofenamic acid may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antrafenine.Approved
ApixabanMeclofenamic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Meclofenamic acid.Investigational
ApramycinMeclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Meclofenamic acid.Approved, Investigational
ArbekacinMeclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMeclofenamic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMeclofenamic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineMeclofenamic acid may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Atamestane.Investigational
AtenololMeclofenamic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Meclofenamic acid.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Meclofenamic acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Meclofenamic acid.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Balsalazide.Approved, Investigational
BazedoxifeneMeclofenamic acid may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminMeclofenamic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMeclofenamic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMeclofenamic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Meclofenamic acid.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Meclofenamic acid.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Meclofenamic acid.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Meclofenamic acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Meclofenamic acid.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMeclofenamic acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Meclofenamic acid.Approved, Investigational
BevantololMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Meclofenamic acid.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
BisoprololMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMeclofenamic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Meclofenamic acid.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Meclofenamic acid.Investigational
BucindololMeclofenamic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bufexamac.Approved, Experimental
BufuralolMeclofenamic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Meclofenamic acid.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Meclofenamic acid.Approved
BupranololMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Meclofenamic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Meclofenamic acid.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.Approved, Vet Approved, Withdrawn
CarteololMeclofenamic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMeclofenamic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Meclofenamic acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meclofenamic acid.Approved, Investigational
CeliprololMeclofenamic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMeclofenamic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
ChlorotrianiseneMeclofenamic acid may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cimicoxib.Investigational
CinoxacinMeclofenamic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinMeclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Meclofenamic acid.Approved
Citric AcidMeclofenamic acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Meclofenamic acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meclofenamic acid.Vet Approved
CloranololMeclofenamic acid may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneMeclofenamic acid may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensMeclofenamic acid may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Meclofenamic acid.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Meclofenamic acid.Experimental
CyclosporineMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinMeclofenamic acid may increase the thrombogenic activities of Daidzein.Experimental
DalteparinMeclofenamic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMeclofenamic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Meclofenamic acid.Investigational
DarexabanMeclofenamic acid may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Delapril.Experimental
DesipramineMeclofenamic acid may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinMeclofenamic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid.Approved, Investigational
DextranMeclofenamic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinMeclofenamic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.Approved, Vet Approved
DicoumarolMeclofenamic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolMeclofenamic acid may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolMeclofenamic acid may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Meclofenamic acid.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.Approved
DihydrostreptomycinMeclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Meclofenamic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid.Approved
DiphenadioneMeclofenamic acid may increase the anticoagulant activities of Diphenadione.Experimental
DrospirenoneMeclofenamic acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Meclofenamic acid.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Meclofenamic acid.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Meclofenamic acid.Investigational
Edetic AcidMeclofenamic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMeclofenamic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat.Approved
EnoxacinMeclofenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMeclofenamic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Meclofenamic acid.Experimental
EpanololMeclofenamic acid may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolMeclofenamic acid may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Meclofenamic acid.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Meclofenamic acid.Experimental
EplerenoneMeclofenamic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin.Approved
EquolMeclofenamic acid may increase the thrombogenic activities of Equol.Investigational
EsatenololMeclofenamic acid may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
EsmololMeclofenamic acid may decrease the antihypertensive activities of Esmolol.Approved
EstradiolMeclofenamic acid may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateMeclofenamic acid may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateMeclofenamic acid may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateMeclofenamic acid may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolMeclofenamic acid may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedMeclofenamic acid may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Meclofenamic acid.Experimental
Ethinyl EstradiolMeclofenamic acid may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Meclofenamic acid.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Meclofenamic acid.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Meclofenamic acid.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Meclofenamic acid.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Meclofenamic acid.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Meclofenamic acid.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Meclofenamic acid.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Meclofenamic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Meclofenamic acid.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Meclofenamic acid.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Meclofenamic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Meclofenamic acid.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fish oil.Approved, Nutraceutical
FleroxacinMeclofenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone.Approved, Investigational
FluindioneMeclofenamic acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineMeclofenamic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Meclofenamic acid.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Meclofenamic acid.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Meclofenamic acid.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Meclofenamic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone propionate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMeclofenamic acid may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumMeclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fosinopril.Approved
FramycetinMeclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
GabexateMeclofenamic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMeclofenamic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid.Approved, Withdrawn
GemifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMeclofenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinMeclofenamic acid may increase the thrombogenic activities of Genistein.Investigational
GentamicinMeclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMeclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Meclofenamic acid.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HE3286.Investigational
HeparinMeclofenamic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolMeclofenamic acid may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Meclofenamic acid.Investigational
HydralazineMeclofenamic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
Hygromycin BMeclofenamic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Meclofenamic acid.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Meclofenamic acid.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icosapent.Approved, Nutraceutical
IdraparinuxMeclofenamic acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Meclofenamic acid.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Meclofenamic acid.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.Approved
IndenololMeclofenamic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Meclofenamic acid.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Meclofenamic acid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.Approved, Investigational
IsepamicinMeclofenamic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Meclofenamic acid.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Istaroxime.Investigational
KanamycinMeclofenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Meclofenamic acid.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.Approved
LabetalolMeclofenamic acid may decrease the antihypertensive activities of Labetalol.Approved
LandiololMeclofenamic acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Meclofenamic acid.Approved, Investigational
LepirudinMeclofenamic acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMeclofenamic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololMeclofenamic acid may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololMeclofenamic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMeclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Meclofenamic acid.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.Approved
LomefloxacinMeclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Meclofenamic acid.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Meclofenamic acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Meclofenamic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.Approved
MelagatranMeclofenamic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.Approved, Vet Approved
MepindololMeclofenamic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Meclofenamic acid.Approved
MestranolMeclofenamic acid may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Meclofenamic acid.Approved, Investigational, Withdrawn
MethallenestrilMeclofenamic acid may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.Approved
MetoprololMeclofenamic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinMeclofenamic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meclofenamic acid.Approved, Experimental
MilnacipranMilnacipran may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Meclofenamic acid.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Meclofenamic acid.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid.Approved
MoxestrolMeclofenamic acid may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meclofenamic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Meclofenamic acid.Approved
NadololMeclofenamic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMeclofenamic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Meclofenamic acid.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid.Approved
Nalidixic AcidMeclofenamic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022.Investigational
NeamineMeclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMeclofenamic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Meclofenamic acid.Approved, Withdrawn
NemonoxacinMeclofenamic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMeclofenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Meclofenamic acid.Approved, Investigational
NetilmicinMeclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Meclofenamic acid.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Meclofenamic acid.Investigational
NorfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Meclofenamic acid.Vet Approved
OtamixabanMeclofenamic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.Approved
Oxolinic acidMeclofenamic acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMeclofenamic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Meclofenamic acid.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Meclofenamic acid.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib.Approved
ParomomycinMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Meclofenamic acid.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Meclofenamic acid.Approved, Investigational
PazufloxacinMeclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMeclofenamic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMeclofenamic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMeclofenamic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Perindopril.Approved
PhenindioneMeclofenamic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMeclofenamic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.Approved, Investigational
PindololMeclofenamic acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidMeclofenamic acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Meclofenamic acid.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Meclofenamic acid.Approved, Investigational
Piromidic acidMeclofenamic acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Meclofenamic acid.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorMeclofenamic acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMeclofenamic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
Polyestradiol phosphateMeclofenamic acid may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pomalidomide.Approved
Potassium CitrateMeclofenamic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololMeclofenamic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Meclofenamic acid.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Meclofenamic acid.Experimental
PromestrieneMeclofenamic acid may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Meclofenamic acid.Approved, Investigational
PropafenoneMeclofenamic acid may decrease the antihypertensive activities of Propafenone.Approved
PropranololMeclofenamic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Meclofenamic acid.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Meclofenamic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meclofenamic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meclofenamic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Meclofenamic acid.Vet Approved
Protein CMeclofenamic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanMeclofenamic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMeclofenamic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Meclofenamic acid.Investigational
PuromycinMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Quinapril.Approved, Investigational
QuinestrolMeclofenamic acid may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMeclofenamic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.Approved, Investigational
RivaroxabanMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Meclofenamic acid.Approved, Investigational, Withdrawn
RosoxacinMeclofenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinMeclofenamic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Meclofenamic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Meclofenamic acid.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Meclofenamic acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Meclofenamic acid.Approved, Investigational
SecoisolariciresinolMeclofenamic acid may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Meclofenamic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Meclofenamic acid.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Meclofenamic acid.Investigational
SertralineSertraline may increase the antiplatelet activities of Meclofenamic acid.Approved
SisomicinMeclofenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateMeclofenamic acid may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Meclofenamic acid.Approved
SotalolMeclofenamic acid may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Spirapril.Approved
SpironolactoneMeclofenamic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Meclofenamic acid.Investigational
StreptomycinMeclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.Approved, Investigational
SulodexideMeclofenamic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Meclofenamic acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Meclofenamic acid.Experimental
Synthetic Conjugated Estrogens, AMeclofenamic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BMeclofenamic acid may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusMeclofenamic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Meclofenamic acid.Approved
TalinololMeclofenamic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Meclofenamic acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.Approved, Investigational
TemafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Meclofenamic acid.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Meclofenamic acid.Vet Approved
TerbutalineMeclofenamic acid may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Meclofenamic acid.Approved
TertatololMeclofenamic acid may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.Approved
TiboloneMeclofenamic acid may increase the thrombogenic activities of Tibolone.Approved, Investigational
Tiludronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMeclofenamic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Meclofenamic acid.Investigational
TioclomarolMeclofenamic acid may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tixocortol.Approved, Withdrawn
TobramycinMeclofenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Meclofenamic acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Meclofenamic acid.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Meclofenamic acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMeclofenamic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Meclofenamic acid.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Meclofenamic acid.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trolamine salicylate.Approved
TrovafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMeclofenamic acid may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Meclofenamic acid.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meclofenamic acid.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Meclofenamic acid.Approved
WarfarinMeclofenamic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMeclofenamic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Meclofenamic acid.Approved, Investigational
ZeranolMeclofenamic acid may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Meclofenamic acid.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Meclofenamic acid.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,313,848.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015074
KEGG Drug
D02341
KEGG Compound
C07117
PubChem Compound
4037
PubChem Substance
46507887
ChemSpider
3897
BindingDB
22971
ChEBI
6710
ChEMBL
CHEMBL509
Therapeutic Targets Database
DNC000919
PharmGKB
PA450341
HET
JMS
RxList
RxList Drug Page
Wikipedia
Meclofenamic_acid
ATC Codes
M01AG04 — Meclofenamic acidM02AA18 — Meclofenamic acid
PDB Entries
3r6i / 4n6p / 4qkn / 5ikq
MSDS
Download (74.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Enrolling by InvitationTreatmentBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
Not AvailableActive Not RecruitingTreatmentProgressive Brain Metastases / Recurrent Brain Metastases1

Pharmacoeconomics

Manufacturers
  • Quantum pharmics ltd
  • American therapeutics inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Parke davis div warner lambert co
Packagers
  • Dispensing Solutions
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Sandhills Packaging Inc.
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral50 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248-250U.S. Patent 3,313,848.
water solubility30 mg/LMERCK INDEX (1996)
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00366 mg/mLALOGPS
logP5.11ALOGPS
logP6.09ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.79ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity76.45 m3·mol-1ChemAxon
Polarizability28.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9393
Blood Brain Barrier+0.8668
Caco-2 permeable+0.8398
P-glycoprotein substrateNon-substrate0.806
P-glycoprotein inhibitor INon-inhibitor0.8943
P-glycoprotein inhibitor IINon-inhibitor0.9474
Renal organic cation transporterNon-inhibitor0.9094
CYP450 2C9 substrateNon-substrate0.6402
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.6566
CYP450 1A2 substrateInhibitor0.9236
CYP450 2C9 inhibitorInhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.8271
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.558
Ames testNon AMES toxic0.8633
CarcinogenicityNon-carcinogens0.5329
BiodegradationNot ready biodegradable0.9709
Rat acute toxicity3.0345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-dc6d0aaa7ee199899830
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0090000000-4f2a28033e59bab0257a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0190000000-b6abcaff657bfa67b599
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03fr-0690000000-eccbe792d08156c89c39
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0920000000-fdcf8eff9ac77cf86d5b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-77140947d50a131a9be6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0900000000-5d2a4942eea2a2d2f252
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0090000000-85032b374ac40bac481a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004l-0090000000-a2cbafbde1150bf5812e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0090000000-47d80abc4f95a2c5ef4c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0090000000-cfa40a800c6a52f6a264
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0290000000-2e34cb2892f6263b39fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0563-0980000000-54fb4017b6a67acb639b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0910000000-26fefd3e49fc0ba3e36e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-1900000000-448908b1e79c92a656d7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-2900000000-71b13766bf05541800b4

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Aminobenzoic acids
Alternative Parents
Benzoic acids / Aminotoluenes / Aniline and substituted anilines / Dichlorobenzenes / Benzoyl derivatives / Aryl chlorides / Vinylogous amides / Amino acids / Secondary amines / Monocarboxylic acids and derivatives
show 6 more
Substituents
Aminobenzoic acid / Benzoic acid / Benzoyl / 1,3-dichlorobenzene / Aniline or substituted anilines / Aminotoluene / Toluene / Chlorobenzene / Halobenzene / Aryl chloride
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
organochlorine compound, secondary amino compound, aminobenzoic acid (CHEBI:6710)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961]
  2. Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
  4. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
  5. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181]
  2. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
  4. Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292]
  5. Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679]
  2. Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Voltage-gated potassium channel activity
Specific Function
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current...
Gene Name
KCNQ2
Uniprot ID
O43526
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 2
Molecular Weight
95846.575 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Voltage-gated potassium channel activity
Specific Function
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native ...
Gene Name
KCNQ3
Uniprot ID
O43525
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 3
Molecular Weight
96741.515 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Thyroid hormone transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-gluc...
Gene Name
SLCO1C1
Uniprot ID
Q9NYB5
Uniprot Name
Solute carrier organic anion transporter family member 1C1
Molecular Weight
78695.625 Da
References
  1. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 09:36